Stocks›Healthcare›PHVS

PHVS

Pharvaris N.V.

NasdaqResearch view

Healthcare · Pharmaceutical Preparations

Price history

Chart: TradingView’s own feed · page prices: 1D EOD

🔒 Click to interact · scroll moves the page

Snapshot

SEC EDGAR

SectorHealthcare

Income—

Sales—

Book/sh—

Cash/sh—

Dividend TTM—

Payout—

Employees—

IPO—

Quick Ratio—

Current Ratio—

Debt/Eq—

EPS (ttm)—

EPS this Y—

EPS past 3/5Y—

Sales past 3/5Y—

EPS Y/Y TTM—

Sales Y/Y TTM—

Shs Outstand—

ROA—

ROE—

ROIC—

Gross Margin—

Oper. Margin—

Profit Margin—

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue & Earnings — fiscal year

Revenue history unavailable.

Follow the news. Track the move.

PHVS story timeline

Company updates and connected market context, with the dated price move attached.

Stories

Direct

Sector context/Earnings

Sep 8

Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks

Pharvaris said its pivotal CHAPTER-3 Phase 3 study of deucrictibant XR met its primary endpoint with statistically significant and clinically meaningful topline results in preventing hereditary angioedema attacks. The result strengthens the case for Pharvaris’s oral prophylaxis program, but the magnitude and full safety detail remain undisclosed in the announcement excerpt.

Price history unavailable

GlobeNewswire · 3h ago

View both sides →

Follow the news. Track the move.